Physician profile
Nassir A Azimi
NPI 1366438764
$778,997.48
in general payments reported to CMS, 2019-2025
70 companies · $77K in 2025
The $77K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170K · 2020: $63K · 2021: $70K · 2022: $151K · 2023: $149K · 2024: $99K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $236K · Travel and Lodging: $36K · Consulting Fee: $31K · Food and Beverage: $23K · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $235,649.00 |
| Travel and Lodging | $35,670.73 |
| Consulting Fee | $30,716.73 |
| Food and Beverage | $22,797.04 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $348,448.06 | 2019-2024 | Xarelto |
| Daiichi Sankyo INC. | $138,759.20 | 2019-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $128,887.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $61,617.16 | 2019-2025 | Andexxa, Farxiga, Tezspire |
| Cardinal Health 200 LLC | $15,292.96 | 2019-2021 | |
| American Regent | $14,369.73 | 2024 | Injectafer |
| Esperion Therapeutics, INC. | $12,354.15 | 2020-2025 | Nexletol, Nexlizet |
| Pharmacosmos Therapeutics INC. | $11,710.55 | 2021-2023 | Monoferric |
| Cvrx, INC. | $10,596.91 | 2021-2025 | Barostim Neo System |
| Novo Nordisk INC | $8,036.40 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6,486.05 | 2019-2025 | Lifevest |
| Edwards Lifesciences Corporation | $2,030.76 | 2019-2025 | Sapien 3 Ultra Resilia |
| W. L. Gore & Associates, INC. | $1,651.40 | 2021-2022 | |
| Boston Scientific Corporation | $1,404.36 | 2019-2024 | Watchman Access System, Watchman Flx, Versacross Access Solution |
| Novartis Pharmaceuticals Corporation | $1,246.16 | 2020-2024 |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $1,162.71 | 2019-2023 | |
| Medtronic, INC. | $1,136.67 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,108.37 | 2019-2025 | Jardiance |
| Amgen INC. | $1,069.73 | 2020-2025 | Repatha, Repatha |
| Abbott Laboratories | $1,064.93 | 2019-2025 | Esprit, Xience Skypoint, Perclose Prostyle |
| Merck Sharp & Dohme LLC | $889.29 | 2021-2025 | Verquvo, Winrevair, Bridion |
| Pfizer INC. | $735.49 | 2019-2025 | |
| Biotronik INC. | $615.18 | 2019-2024 | Biomonitor |
| La Jolla Pharmaceutical Company | $535.39 | 2021-2025 | Giapreza |
| E.R. Squibb & Sons, L.L.C. | $506.06 | 2019-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $486.45 | 2019-2025 | Uptravi, Opsumit |
| Lexicon Pharmaceuticals, INC. | $454.39 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $443.09 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $390.39 | 2022-2025 | Amvuttra |
| Abiomed | $385.18 | 2020-2025 | Impella |
| Glaxosmithkline, LLC. | $381.88 | 2024-2025 | Arexvy, Nucala, Shingrix |
| Kowa Pharmaceuticals America, INC. | $361.38 | 2019-2023 | Livalo |
| Amarin Pharma, INC. | $330.25 | 2019-2022 | |
| Medtronic Vascular, INC. | $315.24 | 2019-2020 | |
| Aop Health US, LLC | $270.40 | 2025 | Rapiblyk |
| Genzyme Corporation | $246.49 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $233.87 | 2019-2025 | Evkeeza |
| Chiesi USA, INC. | $231.34 | 2022-2025 | Cleviprex, Juxtapid |
| United Therapeutics Corporation | $214.99 | 2022-2023 | |
| Penumbra, INC. | $160.33 | 2024 | Indigo System |
| Ekos Corporation | $138.89 | 2019 | |
| Lilly USA, LLC | $135.70 | 2025 | Mounjaro, Zepbound |
| Scpharmaceuticals INC. | $132.97 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $132.92 | 2021 | |
| Kestra Medical Technology Services, INC. | $130.94 | 2022-2025 | Assure Wcd |
| Inari Medical, INC. | $126.53 | 2021-2022 | |
| Gilead Sciences, INC. | $125.00 | 2024 | Veklury |
| Ucb, INC. | $125.00 | 2025 | Nayzilam |
| Sunovion Pharmaceuticals INC. | $125.00 | 2019 | |
| Melinta Therapeutics, LLC | $124.78 | 2022 | |
| Acera Surgical, INC. | $106.95 | 2023 | Restrata Wound Matrix |
| Bridgebio Pharma, INC. | $106.05 | 2025 | Attruby |
| Zoll Circulation INC | $98.28 | 2021 | |
| Baxter Healthcare | $94.99 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Volara System |
| Inspire Medical Systems, INC. | $83.92 | 2024-2025 | Inspire |
| Kiniksa Pharmaceuticals, Ltd. | $78.99 | 2021-2023 | Arcalyst |
| Janssen Scientific Affairs, LLC | $66.45 | 2019 | |
| Itamar Medical INC | $62.99 | 2022-2025 | Watchpatone |
| Impulse Dynamics (USA) INC. | $55.72 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $52.87 | 2024 | Arcalyst |
| Otsuka America Pharmaceutical, INC. | $49.42 | 2019 | |
| Aimmune Therapeutics, INC. | $47.91 | 2025 | Vowst |
| Azurity Pharmaceuticals, INC. | $38.20 | 2025 | Edarbi |
| Mannkind Corporation | $24.64 | 2025 | |
| Altathera Pharmaceuticals LLC | $24.13 | 2025 | Sotalol Hydrochloride |
| Microtransponder, INC. | $22.79 | 2025 | |
| Cardiovascular Systems INC. | $21.17 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.71 | 2020 | |
| Bardy Diagnostics, INC. | $14.00 | 2021 | |
| Bard Peripheral Vascular, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nassir Azimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.